# Canagliflozin Targeting Vascular Inflammation

> **NCT05427084** · PHASE2,PHASE3 · RECRUITING · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 24 (estimated)

## Conditions studied

- Diabetes Type 2
- Coronary Artery Disease

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05427084
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05427084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05427084, "Canagliflozin Targeting Vascular Inflammation". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05427084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*